Cancer Conversations that Matter, Toronto, ON, November 19, 2016

The Canadian Cancer Action Network (CCAN), in collaboration with CADTH, is pleased to invite you to a free, interactive workshop on how cancer drugs are reviewed through CADTH’s pan-Canadian Oncology Drug Review (pCODR) process.

October 25, 2016, 1:00 p.m. to 4:00 p.m., Grand Hotel & Suites Toronto, 225 Jarvis St, Toronto, Ontario

RSVP: Please confirm your attendance at this workshop session via email at, by October 20, 2016.

This is an opportunity for participants to:

  • Meet with the Health Technology Assessment Patient Engagement Navigator (HTAPEN), and  become familiar with the resources and tools available to support a patient submission to pCODR
  • Get best practices, tips, and advice on how to plan and make a patient submission to pCODR
  • Understand how cancer drugs are approved in Canada, with a focus on the pCODR process
  • Learn how costs and benefits are considered in the health technology assessment (HTA) process, with a focus on cancer drugs
  • Obtain insight directly from the patient members of the pCODR Expert Review Committee (pERC) on how patient evidence and information make a difference to the Committee’s recommendations.

Participants will have an opportunity to take part in a case study to understand the HTA recommendation process and to gain insight on how HTA committees make a funding recommendation for a cancer drug. Participants will have the chance to follow the deliberative framework used by pERC, which examines the overall clinical benefit, alignment of patient values, cost-effectiveness, and implementation considerations.

We encourage you to review the Tutorial: How Cancer Drug Funding Decisions Are Made, to help you get the most from the workshop.